215 related articles for article (PubMed ID: 18020539)
1. Refill rates and budget impact of glaucoma lipid therapy: a retrospective database analysis.
Walt JG; Wilensky JT; Fiscella R; Chiang TH; Guckian A
Clin Drug Investig; 2007; 27(12):819-25. PubMed ID: 18020539
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications.
Noecker RJ; Walt JG
Am J Ophthalmol; 2006 Jan; 141(1 Suppl):S15-21. PubMed ID: 16389056
[TBL] [Abstract][Full Text] [Related]
3. Pharmacoeconomic analysis of prostaglandin and prostamide therapy for patients with glaucoma or ocular hypertension.
Frenkel RE; Frenkel M; Toler A
BMC Ophthalmol; 2007 Sep; 7():16. PubMed ID: 17900371
[TBL] [Abstract][Full Text] [Related]
4. Hyperemia-associated costs of medication changes in glaucoma patients treated initially with prostaglandin analogs.
Schwartz GF; Tan J; Kotak S
J Ocul Pharmacol Ther; 2009 Dec; 25(6):555-61. PubMed ID: 20028264
[TBL] [Abstract][Full Text] [Related]
5. Cost-offset analysis: bimatoprost versus other prostaglandin analogues in open-angle glaucoma.
Berenson KL; Kymes S; Hollander DA; Fiscella R; Burk C; Patel VD
Am J Manag Care; 2011 Sep; 17(9):e365-74. PubMed ID: 21902444
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications.
Kymes S
Am J Ophthalmol; 2006 Aug; 142(2):354; author reply 354-5. PubMed ID: 16876536
[No Abstract] [Full Text] [Related]
7. A cost-effectiveness analysis of fixed-combination therapies in patients with open-angle glaucoma: a European perspective.
Hommer A; Wickstrøm J; Friis MM; Steeds C; Thygesen J; Ferreras A; Gouws P; Buchholz P
Curr Med Res Opin; 2008 Apr; 24(4):1057-63. PubMed ID: 18315942
[TBL] [Abstract][Full Text] [Related]
8. [The more favourable cost/effectiveness ratio of latanoprost vs bimatoprost and travoprost when using normally for treatment of glaucoma].
Soto J
Arch Soc Esp Oftalmol; 2005 Jan; 80(1):9-10; author reply 10. PubMed ID: 15692888
[No Abstract] [Full Text] [Related]
9. Efficiency of instillation methods for prostaglandin medications.
Fiscella R; Wilensky JT; Chiang TH; Walt JG
J Ocul Pharmacol Ther; 2006 Dec; 22(6):477-82. PubMed ID: 17238816
[TBL] [Abstract][Full Text] [Related]
10. Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost.
Covert D; Robin AL
Curr Med Res Opin; 2006 May; 22(5):971-6. PubMed ID: 16709319
[TBL] [Abstract][Full Text] [Related]
11. The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries.
Holmstrom S; Buchholz P; Walt J; Wickstrøm J; Aagren M
Curr Med Res Opin; 2006 May; 22(5):897-905. PubMed ID: 16709311
[TBL] [Abstract][Full Text] [Related]
12. Additivity of bimatoprost or travoprost to latanoprost in glaucomatous monkey eyes.
Gagliuso DJ; Wang RF; Mittag TW; Podos SM
Arch Ophthalmol; 2004 Sep; 122(9):1342-7. PubMed ID: 15364714
[TBL] [Abstract][Full Text] [Related]
13. Estimated comparative costs of achieving a 20% reduction in intraocular pressure with bimatoprost or latanoprost in patients with glaucoma or ocular hypertension.
Fiscella R; Walt J
Drugs Aging; 2006; 23(1):39-47. PubMed ID: 16492068
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France.
Payet S; Denis P; Berdeaux G; Launois R
Clin Drug Investig; 2008; 28(3):183-98. PubMed ID: 18266403
[TBL] [Abstract][Full Text] [Related]
15. Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study.
Reardon G; Schwartz GF; Mozaffari E
Clin Ther; 2003 Apr; 25(4):1172-85. PubMed ID: 12809964
[TBL] [Abstract][Full Text] [Related]
16. First-year treatment patterns among new initiators of topical prostaglandin analogs.
Schmier JK; Covert DW; Robin AL
Curr Med Res Opin; 2009 Apr; 25(4):851-8. PubMed ID: 19231912
[TBL] [Abstract][Full Text] [Related]
17. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study.
Parrish RK; Palmberg P; Sheu WP;
Am J Ophthalmol; 2003 May; 135(5):688-703. PubMed ID: 12719078
[TBL] [Abstract][Full Text] [Related]
18. Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs.
Eisenberg DL; Toris CB; Camras CB
Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S105-15. PubMed ID: 12204706
[TBL] [Abstract][Full Text] [Related]
19. A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension.
Walt JG; Lee JT
Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S36-44. PubMed ID: 15016560
[TBL] [Abstract][Full Text] [Related]
20. Long-term medical management of primary open-angle glaucoma and ocular hypertension in the UK: optimizing cost-effectiveness and clinic resources by minimizing therapy switches.
Orme M; Collins S; Loftus J
J Glaucoma; 2012 Sep; 21(7):433-49. PubMed ID: 21677590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
